Arcutis missed EPS expectations because SG&A jumped to $99.6 million from $62.4 million a year ago to fund a new primary care and pediatric sales force. Revenue still grew 45% and management raised full-year net product sales guidance to $535 million to $545 million, with an FDA decision on ZORYVE cream for infants due February 23, 2027.
Latest Activity
ARQT Coverage
Insiders Snap Up $54M in Biotech and Offshore Driller Stocks
In the past week or so, some public offerings prompted huge insider buying. However, these were not the only notable insider purchases recently.
Wednesday’s Top Analyst Upgrades and Downgrades: Masco, Micron, Plug Power, Smith & Wesson, Virgin Galactic and More
Wednesday’s top analyst upgrades and downgrades included Allegro, Jinkosolar, Masco, Micron Technology, Plug Power, Smith & Wesson and Virgin Galactic.
Thursday’s Top Analyst Upgrades and Downgrades: Airbnb, CrowdStrike, DoorDash, Ford, Fortinet, Intuit, T-Mobile, Twilio, Zscaler and More
Thursday's top analyst upgrades and downgrades included Airbnb, CrowdStrike, DoorDash, Ford, Intuit, Lumber Liquidators, Occidental Petroleum, T-Mobile, Twilio, Uber and UBS.
Top Analyst Upgrades and Downgrades: Arcutis, DraftKings, First Solar, InflaRx, Livent, Medtronic, NextEra, Roku, Snowflake, Tesla and More
Thursday's top analyst upgrades and downgrades included Arcutis Biotherapeutics, DraftKings, First Solar, InflaRx, Livent, Medtronic, NextEra Energy Partners, Roku, Snowflake and Tesla.
6 Secondary Offerings Making Big Moves in Stocks
24/7 Wall St. tracked six new secondary offerings that were announced after the close on Tuesday, September 29, 2020.